52 ADHD Facts & Statistics: How Common Is ADHD?

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that affects both children and adults. It is characterized by symptoms of inattention, impulsivity, and hyperactivity. In this article, we will explore key statistics related to ADHD and delve deeper into various aspects of the condition.

Key ADHD Statistics

1. Approximately 5% of children worldwide are diagnosed with ADHD.
2. ADHD is one of the most common neurodevelopmental disorders in children.
3. In the United States, 9.4% of children aged 2-17 have been diagnosed with ADHD.
4. Boys are more likely to be diagnosed with ADHD than girls, with a ratio of about 2:1.
5. About 50% of children with ADHD continue to have symptoms into adulthood.
6. Approximately 2.5% of adults are diagnosed with ADHD.
7. ADHD diagnosis rates have increased by 42% between 2003 and 2011.
8. Children with ADHD are more likely to experience learning difficulties, with 20-30% having a specific learning disorder.
9. 65% of children with ADHD have at least one other co-existing mental health condition.
10. Adults with ADHD are more likely to have a history of substance abuse, with rates ranging from 15% to 50%.
11. ADHD is estimated to cost the United States between $143 billion and $266 billion each year in health care expenses, lost productivity, and other societal costs.
12. Stimulant medications are the most common treatment for ADHD, with 62% of children with ADHD in the US receiving medication.
13. Non-stimulant medications, such as atomoxetine, are also used to treat ADHD and can be effective for some individuals who do not respond well to stimulants.
14. Behavioral therapy is an important component of ADHD treatment and can be effective in improving symptoms for both children and adults.
15. Early intervention and a multimodal treatment approach, including medication, therapy, and support, can improve long-term outcomes for individuals with ADHD.

How Common is ADHD?

ADHD is a prevalent neurodevelopmental disorder affecting millions of people across the globe.

Prevalence of ADHD in Children

• In Europe, ADHD prevalence among children ranges from 2.2% to 5.5%, depending on the country and diagnostic criteria used.
• In Australia, around 7.4% of children aged 4-17 have been diagnosed with ADHD.
• In Asia, the prevalence of ADHD in children varies widely across countries but has been estimated to be around 6.3% overall.

Prevalence of ADHD in Adults

• Adult ADHD prevalence in the United States is estimated at around 4.4%.
• In Europe, adult ADHD prevalence ranges from 1.2% to 7.3%, depending on the country and diagnostic criteria used.
• A study conducted in China reported an adult ADHD prevalence rate of approximately 3.5%.

ADHD Prevalence Across Different Age Groups

• Overall, the global prevalence of ADHD is estimated to be around 5.29% in children and adolescents, and 2.8% in adults (source: Polanczyk et al., 2014).
• In preschool-aged children (2-5 years old), ADHD prevalence is approximately 2.4% (source: Danielson et al., 2018).
• Among school-aged children (6-11 years old), ADHD prevalence increases to about 9.6% (source: Danielson et al., 2018).
• In adolescents aged 12-17, the prevalence of ADHD is around 13.6% (source: Danielson et al., 2018).
• The prevalence of ADHD in young adults aged 18-24 is estimated to be approximately 4.2% (source: Kessler et al., 2006).
• Among adults aged 25 and older, the prevalence of ADHD ranges from about 2.5% to 3.5%, with rates decreasing slightly with age (source: Kessler et al., 2006; Fayyad et al., 2017).

Overall Prevalence and by Gender

• The global prevalence of ADHD is estimated to be around 5.29% in children and adolescents, and 2.8% in adults.
• In the United States, 9.4% of children aged 2-17 have been diagnosed with ADHD.
• Boys are more likely to be diagnosed with ADHD than girls, with a ratio of about 2:1.
• Adult ADHD prevalence in the United States is estimated at around 4.4%.
• In Europe, adult ADHD prevalence ranges from 1.2% to 7.3%, depending on the country and diagnostic criteria used.

Overall Prevalence and by Race/Ethnicity

• In the United States, the prevalence of ADHD varies among different racial and ethnic groups. According to a report by the Centers for Disease Control and Prevention (CDC), the estimated prevalence of ADHD in children aged 2-17 is as follows:

1. Non-Hispanic white: 8.8%
2. Non-Hispanic black: 9.5%
3. Hispanic: 6.3%
4. Non-Hispanic Asian: 4.2%

• A study conducted in Canada found that the prevalence of ADHD was higher among children from lower-income families, Indigenous children, and those with immigrant backgrounds.
• The prevalence of ADHD in other countries also varies by race/ethnicity. For example, a study conducted in Brazil found that the prevalence of ADHD was higher among non-white children compared to white children.

Prevalence of Comorbidities in ADHD

Individuals with ADHD are more likely to have comorbidities, or the presence of two or more co-existing conditions. The following statistics provide insights into the prevalence of individuals with ADHD that have comorbidities:

• 65% of children with ADHD have at least one other co-existing mental health condition.
• The most common psychiatric comorbidities in children with ADHD are oppositional defiant disorder (ODD), anxiety disorders, and mood disorders.
• Among adults with ADHD, approximately 50% have at least one other psychiatric disorder, such as anxiety, depression, and substance use disorder.
• The lifetime prevalence of substance use disorders is higher among adults with ADHD than those without ADHD.
• Individuals with ADHD are also at increased risk for sleep problems and learning disabilities.

Treatment for ADHD in Children

• Stimulant medications are the most common treatment for ADHD in children, with 62% of children with ADHD in the US receiving medication.
• Non-stimulant medications, such as atomoxetine, guanfacine, and clonidine, are also used to treat ADHD in children and can be effective for some individuals who do not respond well to stimulants.
• Behavioral therapy is an important component of ADHD treatment in children and can be effective in improving symptoms, academic performance, social skills, and family relationships.
• Parent training programs can help parents learn effective parenting strategies to manage their child's behavior and improve communication.
• School-based interventions can also be helpful for children with ADHD by providing academic support, accommodations, and behavioral interventions.

Treatment for ADHD in Adults

• Stimulant medications are also commonly used to treat ADHD in adults. However, dosage may need to be adjusted due to differences in metabolism between adults and children.
• Non-stimulant medications such as atomoxetine, bupropion, and certain antidepressants can also be used to treat adult ADHD.
• Cognitive-behavioral therapy (CBT) is often used as a first-line psychosocial treatment for adult ADHD. CBT can help individuals develop coping strategies for managing symptoms related to distractibility, impulsivity, and hyperactivity.
• Coaching is another type of psychosocial intervention that can help adults with ADHD improve time management skills, organization abilities, and goal-setting strategies.

ADHD Medication Statistics

• Stimulant medications, such as methylphenidate and amphetamine, are the most commonly prescribed medications for ADHD.
• In Australia, approximately 70% of children with ADHD who receive treatment are prescribed stimulant medication (source: Australian Institute of Health and Welfare).
• In the United States, 62% of children with ADHD receive medication treatment, and about 80% of those receive stimulant medication (source: CDC).
• Non-stimulant medications, such as atomoxetine and guanfacine, are also used to treat ADHD but are less commonly prescribed than stimulants.
• The use of non-medication treatments for ADHD has been increasing in recent years. For example, a study conducted in Sweden found that between 2007 and 2016, the proportion of children with ADHD who received psychotherapy increased from 8% to 32%, while the proportion receiving medication decreased from 92% to 75% (source: Chen et al., 2020).
• It is estimated that up to one-third of individuals with ADHD do not respond well to medication treatment (source: Kooij et al., 2019).

The Cost of ADHD

• The annual medical cost for a child with ADHD is estimated to be $$2,500-$$4,000 higher than that of a child without ADHD.
• Adults with ADHD also incur higher medical costs, with an estimated annual cost increase of $$1,500-$$2,000 compared to adults without ADHD.
• In the United States, the total societal cost of ADHD in 2019 was estimated to be between $143 billion and $266 billion.
• Direct medical costs account for approximately 25% of the total societal cost of ADHD, while indirect costs such as lost productivity and earnings make up the majority of the remaining costs.
• The economic burden of ADHD is not limited to the United States. A study conducted in Europe found that the estimated annual cost per child with ADHD ranged from €1,242 to €12,005 depending on the severity of symptoms and country-specific healthcare systems.

Conclusion

ADHD is a neurodevelopmental disorder that affects both children and adults. The global prevalence of ADHD in children and adolescents is estimated to be around 5.29%, while the prevalence in adults is approximately 2.8%.

In the United States, 9.4% of children aged 2-17 have been diagnosed with ADHD, and adult ADHD prevalence is estimated at around 4.4%. Boys are more likely to be diagnosed with ADHD than girls, with a ratio of about 2:1.

Individuals with ADHD are also more likely to have comorbidities, such as anxiety disorders, mood disorders, and substance use disorders. Children with ADHD often receive treatment through stimulant medications or behavioral therapy, while adults may also benefit from cognitive-behavioral therapy or coaching sessions.

The economic burden of ADHD is significant, with estimates ranging from $143 billion to $266 billion in the United States alone. Direct medical costs account for only a quarter of this total cost, highlighting the importance of addressing the societal impact of this disorder.

In summary, ADHD is a prevalent disorder affecting individuals across different age groups and races/ethnicities. The high rates of comorbidities and associated costs make it an important public health concern that requires further attention and research.

Sources

• Pelham WE Jr., Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol. 2007;32(6):711–727.
• Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, Erder MH, Neumann PJ. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51(10):990–1002.e2.
• Dalsgaard S, Pérez-Alvarez F, Simonsen M. Economic burden of ADHD: a systematic review. Am J Manag Care. 2019;25(2):e40–e49.
• Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis. The American Journal of Psychiatry. 2007;164(6):942-948.
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Publishing; 2013.
• Centers for Disease Control and Prevention. ADHD Throughout the Years [Internet]. 2018 [cited 2021 Jul 23]. Available from: https://www.cdc.gov/ncbddd/adhd/timeline.html
• Ramtekkar UP, Reiersen AM, Todorov AA, Todd RD. Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11. Journal of the American Academy of Child and Adolescent Psychiatry. 2010;49(3):217-228.
• Biederman J, Petty CR, Clarke A, Lomedico A, Faraone SV. Predictors of persistent ADHD: an 11-year follow-up study. Journal of Psychiatric Research. 2011;45(2):150-155.
• Wilens TE, Dodson W. A Clinical Perspective of Attention-Deficit/Hyperactivity Disorder into Adulthood. Journal of Clinical Psychiatry. 2004;65(10):1301-1313.
• Visser SN, Zablotsky B, Holbrook JR, Danielson ML, Bitsko RH. Diagnostic experiences of children with attention-deficit/hyperactivity disorder. National Health Statistics Reports. 2015;(81):1-7.
• Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. American Journal of Psychiatry. 2008;165(6):721-730.
• Evans, S. W., Owens, J. S., & Bunford, N. (2014). Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. Journal of Clinical Child & Adolescent Psychology, 43(4), 527-551.
• Daley, D., Van Der Oord, S., Ferrin, M., Danckaerts, M., Doepfner, M., Cortese, S., & Sonuga-Barke, E. J. S. (2018). Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder. Journal of Child Psychology and Psychiatry, 59(9), 932-947.
• Australian Institute of Health and Welfare (2018). Australia's children. Canberra: AIHW.
• Danielson et al., "Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016," JAMA Network Open (2018)
• Kessler et al., "Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication," Archives of General Psychiatry (2005)
• Fayyad et al., "Cross-National Prevalence and Correlates of Adult Attention Deficit Hyperactivity Disorder," British Journal of Psychiatry (2017)
• National Institute of Mental Health. "Treatment of attention-deficit/hyperactivity disorder."
• American Academy of Pediatrics. "ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation and Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents."
• Chen Q, Kuja-Halkola R, Sjölander A et al. Pharmacological and non-pharmacological treatment of adult ADHD in Sweden: a nationwide register-based study. BMJ Open 2020;10:e035658.
• Kooij SJ, Bejerot S, Blackwell A et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2019;19:36.

‍